Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 22
2018 21
2019 9
2020 15
2021 14
2022 8
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications.
Toyokawa G, Bersani F, Bironzo P, Picca F, Tabbò F, Haratake N, Takenaka T, Seto T, Yoshizumi T, Novello S, Scagliotti GV, Taulli R. Toyokawa G, et al. Among authors: haratake n. Crit Rev Oncol Hematol. 2023 Apr;184:103966. doi: 10.1016/j.critrevonc.2023.103966. Epub 2023 Mar 15. Crit Rev Oncol Hematol. 2023. PMID: 36925092 Free article. Review.
Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy.
Kodama M, Toyokawa G, Sugahara O, Sugiyama S, Haratake N, Yamada Y, Wada R, Takamori S, Shimokawa M, Takenaka T, Tagawa T, Kittaka H, Tsuruda T, Tanaka K, Komatsu Y, Nakata K, Imado Y, Yamazaki K, Okamoto I, Oda Y, Takahashi M, Izumi Y, Bamba T, Shimizu H, Yoshizumi T, Nakayama KI. Kodama M, et al. Among authors: haratake n. Cell Rep. 2023 Aug 29;42(8):112899. doi: 10.1016/j.celrep.2023.112899. Epub 2023 Aug 1. Cell Rep. 2023. PMID: 37531252 Free article.
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D. Haratake N, et al. J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3. J Thorac Oncol. 2024. PMID: 37924972 Free article.
MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
Nakanishi T, Yoneshima Y, Okamura K, Yanagihara T, Hashisako M, Iwasaki T, Haratake N, Mizusaki S, Ota K, Iwama E, Takenaka T, Tanaka K, Yoshizumi T, Oda Y, Okamoto I. Nakanishi T, et al. Among authors: haratake n. Cancer Sci. 2023 Oct;114(10):4101-4113. doi: 10.1111/cas.15921. Epub 2023 Aug 10. Cancer Sci. 2023. PMID: 37565582 Free PMC article.
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N, Morimoto Y, Fushimi A, Ahmad R, Bhattacharya A, Daimon T, Haratake N, Inoue Y, Ishikawa S, Yamamoto M, Hata T, Akiyoshi S, Hu Q, Liu T, Withers H, Liu S, Shapiro GI, Yoshizumi T, Long MD, Kufe D. Yamashita N, et al. Among authors: haratake n. Mol Cancer Res. 2023 Mar 1;21(3):274-289. doi: 10.1158/1541-7786.MCR-22-0772. Mol Cancer Res. 2023. PMID: 36445328 Free PMC article.
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
Takamori S, Matsubara T, Haratake N, Toyokawa G, Fujishita T, Toyozawa R, Ito K, Yamaguchi M, Taguchi K, Okamoto T, Seto T. Takamori S, et al. Among authors: haratake n. Front Oncol. 2021 Aug 23;11:704084. doi: 10.3389/fonc.2021.704084. eCollection 2021. Front Oncol. 2021. PMID: 34497761 Free PMC article. Review.
99 results